Reports of T cell malignancies after CAR-T cell therapy should be investigated, but existing data from follow-up studies suggest a low risk compared with other cancer treatments.
This is a preview of subscription content, access via your institution
Relevant articles
Open Access articles citing this article.
-
Bispecific antibodies and CAR-T cells: dueling immunotherapies for large B-cell lymphomas
Blood Cancer Journal Open Access 08 February 2024
Access options
Access Nature and 54 other Nature Portfolio journals
Get Nature+, our best-value online-access subscription
$29.99 / 30 days
cancel any time
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Harrison, S. J. Blood 142 (suppl. 1), 6939 (2023).
Li, P. et al. Blood 142 (suppl. 1), 1025 (2023).
Heinrich, T. et al. Mol. Ther. 21, 1160–1168 (2013).
Micklethwaite, K. P. et al. Blood 138, 1391–1405 (2021).
Hsieh, E. M. et al. Blood Adv. 6, 5222–5226 (2022).
Anand, K. et al. J. Immunother. Cancer 8, e000104 (2020).
Chihara, D., Dores, G. M., Flowers, C. R. & Morton, L. M. Blood 138, 785–789 (2021).
Meadows, A. T. et al. J. Clin. Oncol. 27, 2356–2362 (2009).
Brown, J. R. et al. J. Clin. Oncol. 23, 2208–2214 (2005).
Schaapveld, M. et al. N. Engl. J. Med. 373, 2499–2511 (2015).
Spencer Chapman, M. et al. Nat. Med. 29, 3175–3183 (2023).
Lamble, A. J. et al. Blood Adv. 7, 575–585 (2023).
Hamilton, M. P. et al. Am. Soc. Hematol. https://go.nature.com/3GKUITY (2023).
Steffin, D. H. M. et al. Blood 140, 16–24 (2022).
Cornetta, K. et al. Mol. Ther. 31, 801–809 (2023).
Acknowledgements
We thank the executive committees of the ASTCT, EBMT and ISCT for reviewing this commentary. B.L.L. is an immediate past president of the ISCT. D.L.P. is vice president of the ASTCT. M.P.G. is co-chair of the Immuno & Gene Therapy Committee of the ISCT. J.J.B. is co-chair of the Stem Cell Engineering Committee of the ISCT. M.V.M. is chair and F.L.L. is co-chair of the ASTCT Committee on Cellular Therapy. A.M.S. is president of the EBMT. M.-A.P. is president of the ASTCT.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
B.L.L. is an inventor on patents and/or patent applications licensed to Novartis Institutes of Biomedical Research and receives license revenue from such licenses; is a scientific founder of Tmunity Therapeutics and Capstan Therapeutics; and a member of the scientific advisory boards of Akron Biotech, Avectas, Capstan Therapeutics, Cellula Therapeutics, Immuneel Therapeutics, Immusoft, In8bio, Kite Gilead, Ori Biotech, Oxford Biomedica, ThermoFisher Pharma Services, UTC Therapeutics and Vycellix. M.C.P. received research support from Novartis, Kite Pharma, Bristol Myers Squibb, Janssen Consulting: Novartis and Gilead. J.E.C. is a cofounder of Twain Therapeutics, director at Dispatch Therapeutics and 3T Biosciences, and receives research funding from Janssen. D.L.P. reports stock and other ownership interests from Genentech, Roche (spouse former employment); consulting or advisory roles from Novartis, Kite/Gilead, Gerson Lehrman Group and Janssen (Johnson & Johnson), Bristol-Myers Squibb, Bluebird Bio, Angiocrine, Mirror Biologics, Capstan Therapeutics, Instill Bio, Sana Biotechnology and Verismo Therapeutics; received research funding from Novartis and Bristol-Myers Squibb; and reports royalties and other intellectual property from Novartis and Tmunity. D.L.P. is a patent inventor for use of CAR-T cells in CD19+ malignancies, and was chair of the board of directors of the National Marrow Donor Program from October 2018 to October 2020. J.J.B. reports consulting fees from Sanofi, Sobi, SmartImmune, Immusoft, BlueRock, Advanced Clinical, Merck and Bluebird Bio. S.A.G. declares research and/or clinical trial support from Novartis, Servier, Vertex, Cellectis and Kite; and was a member of steering committees, scientific advisory boards or held consulting positions at Novartis, Allogene, Adaptimmune, GlaxoSmithKline, Vertex, Jazz, Kyttaro and Cabaletta. M.V.M. is an inventor on patents related to adoptive cell therapies, held by Massachusetts General Hospital (some licensed to Promab) and the University of Pennsylvania (some licensed to Novartis); reports grant or research support from Kite Pharma and Moderna; reports consulting fees from several companies involved in cell therapies; has equity in 2SeventyBio, A2Bio, Cargo, Century Therapeutics, Neximmune, Oncternal and TCR2; and has served on the board of directors for 2Seventy Bio. F.L.L. has had consulting or advisory roles for Allogene, Amgen, Bluebird Bio, BMS/Celgene, Calibr, Cellular Biomedicine Group, Cowen, ecoR1, Emerging Therapy Solutions Gerson Lehman Group, GammaDelta Therapeutics, Iovance, Janssen, Kite, a Gilead Company, Legend Biotech, Novartis, Umoja and Wugen; serves on a data safety monitoring board for the NCI; receives research funding from Allogene, Kite, BMS, 2seventyBio and Novartis; and has patents and other intellectual property in the field of cellular immunotherapy held by Moffitt Cancer Center. H.E.H. has equity in Marker Therapeutics, Allovir, and CoRegen and serves on scientific advisory boards for March Biosciences, Fresh Wind Biotechnologies and Tikva Allocell. C.L.M. is an inventor on multiple patents related to CAR-T cell therapy and has received royalties for licenses to Juno Therapeutics and CARGO therapeutics. C.L.M. is a co-founder of Lyell Immunopharma, CARGO Therapeutics and Link Cell Therapies, which are developing CAR-T cells and holds equity in these companies. C.L.M. is a consultant for CARGO, Link, Immatics, Ensoma, Adaptimmune and received research funding from Lyell and Tune Therapeutics. C.H.J. is an inventor on patents and/or patent applications licensed to Novartis and receives license revenue from such licenses. C.H.J. is a scientific founder of Tmunity Therapeutics, Dispatch Biotherapeutics, Bluewhale Bio, Marble Therapeutics and Capstan Therapeutics; is a member of the scientific advisory boards of AC Immune, BluesphereBio, Cabaletta, Carisma, Cartography, Cellares, Cellcarta, Celldex, Danaher, Decheng, ImmuneSensor, Kite Gilead, Poseida, Replay Bio, Treadwell Therapeutics, Verismo, Viracta, Vittoria and WIRB-Copernicus; and receives sponsored research support from Kite Gilead. A.M.S. has received research support from Takeda, and honoraria from Takeda, BMS/Celgene, MSD, Novartis, Gilead Kite, Sanofi, Pierre Fabre, Janssen and Jazz Pharmaceuticals. M.-A.P. reports honoraria from Adicet, Allogene, Allovir, Caribou Biosciences, Celgene, Bristol-Myers Squibb, Equilium, Exevir, ImmPACT Bio, Incyte, Karyopharm, Kite/Gilead, Merck, Miltenyi Biotec, MorphoSys, Nektar Therapeutics, Novartis, Omeros, OrcaBio, Sanofi, Syncopation, VectivBio AG and Vor Biopharma; serves on data safety and monitoring boards for Cidara Therapeutics, Medigene and Sellas Life Sciences; and the scientific advisory board of NexImmune. M.-A.P. has ownership interests in NexImmune, Omeros and OrcaBio, and has received institutional research support for clinical trials from Allogene, Incyte, Kite/Gilead, Miltenyi Biotec, Nektar Therapeutics and Novartis. M.C.G., E.M.H., F.C., A.R. and J.S. all have nothing to disclose.
Rights and permissions
About this article
Cite this article
Levine, B.L., Pasquini, M.C., Connolly, J.E. et al. Unanswered questions following reports of secondary malignancies after CAR-T cell therapy. Nat Med 30, 338–341 (2024). https://doi.org/10.1038/s41591-023-02767-w
Published:
Issue Date:
DOI: https://doi.org/10.1038/s41591-023-02767-w
This article is cited by
-
Bispecific antibodies and CAR-T cells: dueling immunotherapies for large B-cell lymphomas
Blood Cancer Journal (2024)
-
Do cutting-edge CAR-T-cell therapies cause cancer? What the data say
Nature (2024)
-
Engineering immune-evasive allogeneic cellular immunotherapies
Nature Reviews Immunology (2024)
-
T cell lymphoma and secondary primary malignancy risk after commercial CAR T cell therapy
Nature Medicine (2024)